Fulgent Genetics

Call Directions Website Contact the business

Fulgent Genetics Fulgent Genetics is a CAP and CLIA certified clinical laboratory in Los Angeles that's dedicated to improving patient care. Why Fulgent ?

Mission
Developing flexible and affordable genetic testing that improves the everyday lives of those around us. Founded in 2011, Fulgent began with two simple ideas; flexibility and affordability. Today, we strive to create the most effective and wide ranging tests on the market. All of this is done in the pursuit of bettering the everyday lives of our customers. We shine brightest when meaningful relationships, passion, and purpose come together. We are committed to working side-by-side with every one of our clients. This is essential to a strong and successful relationship and is our core way of doing business. We have collaborated with some of the top clinicians in our field who have assisted us in creating our panels, report formatting, and improvements to our website. Our approach has always been simple: provide testing based on the specific needs of clinicians and their patients. Customer Support
Our support philosophy has always been simple: answer our client's questions quickly and accurately. We do not have a receptionist or an automated system, we have a dedicated team of customer support staff that can answer a wide variety of questions, so you can spend more time with what is really important, patients.

Reproductive care rarely moves in a straight line. A carrier screen leads to a prenatal question, a prenatal finding lea...
10/23/2026

Reproductive care rarely moves in a straight line. A carrier screen leads to a prenatal question, a prenatal finding leads to a diagnostic one, and sometimes a rare disease workup starts in a newborn.

One Genetics Lab. For Every Step. That's what you can get with Fulgent, and what we'll be at to talk about.

We'll be at booth 507 in Baltimore, October 24–28.

Fulgent's reproductive health tests are laboratory developed tests, developed and validated by Fulgent Therapeutics LLC and performed in our CLIA-certified, CAP-accredited laboratory, unless otherwise indicated. These tests are available through your healthcare provider. See our website (FulgentGenetics.com) for intended use.

We're proud to have two Fulgent posters at   this week, addressing two very different questions.Jay E. Shaw, MS, CGC, is...
10/20/2026

We're proud to have two Fulgent posters at this week, addressing two very different questions.

Jay E. Shaw, MS, CGC, is presenting "Dual diagnosis and beyond: the occurrence of triple and quadruple molecular diagnoses in whole exome and whole genome sequencing – a laboratory experience."
📌 Poster 2030W — Wednesday, October 21, 2:30–4:30 PM EDT

Mitchell W. Dillon, MS, CGC, is presenting "Sounds of silence: RNA sequencing detects potential skewed X-inactivation in female X-linked variant carriers."
📌 Poster 2052T — Thursday, October 22, 4:15–6:15 PM EDT

Stop by either session to talk through the work with them directly.

Thank you to the authors and their co-authors: Jamie Zdrodowski, MS, CGC; Shuxi Liu, PhD, FACMG; Zhenbin Chen, PhD, FACMG; and Elina Nikkola, PhD.

And while you're on the floor, be sure to get the 411 at booth 411!

Heading to ESMO 2026 in Madrid? Let’s meet.Fulgent Genetics will be at Booth 8083, Hall 8. Drop by anytime to talk with ...
10/19/2026

Heading to ESMO 2026 in Madrid? Let’s meet.

Fulgent Genetics will be at Booth 8083, Hall 8. Drop by anytime to talk with our team, or message us to set up a meeting ahead of time.

For biopharma, CROs, and researchers, we support oncology research and clinical trials. For clinicians, we provide testing with a clinical report to support diagnosis and therapeutic guidance. Here’s what we’ll be highlighting:

🔸 Tumor sequencing, HRR/HRD, and liquid biopsy
🔸 RNA sequencing, 10x single cell and spatial, and Olink® proteomics
🔸 Exome and genome sequencing
🔸 Heme NGS and a full pathology suite, including IHC
🔸 CE-marked assay under IVDR covering 6,717 genes, including hereditary cancer genes

Get the 411 at booth 411.We're bringing scientists to  , not just signage! Senior members of our curation team will be h...
10/15/2026

Get the 411 at booth 411.

We're bringing scientists to , not just signage! Senior members of our curation team will be hosting a "Q&A Power Hour" at Fulgent's booth over the course of the expo.

Questions about long-range insights and the technology behind them? Rare or complicated genes? AI-assisted interpretation? Come ask us!

Visit booth 411, October 20–24 in Montreal for full details and our Q&A schedule.

Beacon® Carrier Screening panels are designed to detect risk for severe, early-onset conditions in an individual's or re...
10/12/2026

Beacon® Carrier Screening panels are designed to detect risk for severe, early-onset conditions in an individual's or reproductive pair's offspring.

Beacon Preconception panels cover the same genes and detect that same risk, and add information about the possibility of manifesting carriers — carriers who may have symptoms themselves — and milder forms of the conditions tested. That additional layer makes them a strong fit for fertility clinics, other reproductive providers, and those seeking as much information as possible.

We're always available to discuss which panels are right for your patients.

Explore the Beacon menu: https://web.fulgentgenetics.com/reproductive/beacon-carrier-screening

Beacon Carrier Screening is available through your healthcare provider. Beacon is a laboratory developed test, developed and validated by Fulgent Therapeutics LLC and performed in our CLIA-certified, CAP-accredited laboratory. This test has not been cleared or approved by the FDA.

Breast Cancer Awareness Month campaigns run throughout October, but we know the work runs year-round: patients navigatin...
10/05/2026

Breast Cancer Awareness Month campaigns run throughout October, but we know the work runs year-round: patients navigating a new diagnosis, families asking what a result means for their own risk, and the genetic counselors, oncologists, and lab teams who sit with those questions every day.

We're grateful to be part of that work, and grateful to the advocates, researchers, and clinicians who keep pushing it forward. Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us — and this month is a good reminder of what that means and who it impacts.

If breast cancer runs in your family, talk with your doctor or a genetic counselor about whether genetic testing could be useful for you.

Fulgent Genetics is heading to MDS Congress 2026 in Seoul, South Korea from Oct 4–8! Visit us at Booth  #182 to learn ho...
09/28/2026

Fulgent Genetics is heading to MDS Congress 2026 in Seoul, South Korea from Oct 4–8! Visit us at Booth #182 to learn how our genetic testing solutions & multiomics support the Parkinson's and rare movement disorder community.

We're proud to support advancing research in this space through our contribution to a poster presented by the Parkinson's Foundation's PD GENEration program:

“Evaluating the GBA1 Intronic rs3115534-G PD Risk Variant in the PD GENEration Cohort”

At our booth, our team will be on hand to discuss:

🔸 BioPharma services supporting biomarker discovery, companion diagnostic development, and clinical trial genomics for movement disorder drug programs.

🔸 Custom and NGS panels to support patient stratification and target identification in neurogenetic trials.

🔸 Whole Exome and Whole Genome Sequencing at scale, including FulgentExome (CE-IVD), for clinical applications.

🔸 Whole Genome Sequencing powered by Illumina TruPath for detecting repeat-expansion and structural variants relevant to neurodegenerative mechanisms.

🔸 Fulgent RISE - pairing WES/WGS with RNA sequencing to add transcriptomic insight for biomarker and mechanism-of-action studies.

We look forward to connecting with you!

Booth #182 | MDS Congress 2026 | Oct 4–8

FulgentExome carries CE-IVD marking for clinical use where applicable. Other sequencing and testing services described are offered for research use and/or as laboratory developed tests, as applicable to each service.

Fulgent now offers RFC1 repeat expansion analysis using a two-step approach, built for expansions that can exceed the ra...
09/24/2026

Fulgent now offers RFC1 repeat expansion analysis using a two-step approach, built for expansions that can exceed the range conventional repeat-expansion PCR is designed to cover.

An initial allele-check PCR resolves samples with alleles in the normal size range. Samples not resolved at that step move to long-read sequencing, which characterizes both the motif pattern and the size of the expansion. The assay analyzes for pathogenic expanded motifs (≥250 AAGGG and ≥600 AAAGG) that fall into a range where conventional approaches often reach their limit.

Results are reported as positive for two common expanded alleles, or negative for zero to one expanded allele.

See the full test details: https://www.fulgentgenetics.com/rfc1-repeat-expansion

RFC1 repeat expansion analysis is available through your healthcare provider. This is a laboratory developed test, developed and validated by Fulgent Therapeutics LLC and performed in our CLIA-certified, CAP-accredited laboratory. This test has not been cleared or approved by the FDA.

Fulgent Genetics is joining the Epic Aura network in Q4 2026.  Epic Aura connects performing labs like Fulgent to provid...
09/21/2026

Fulgent Genetics is joining the Epic Aura network in Q4 2026.

Epic Aura connects performing labs like Fulgent to provider organizations using Epic. We're excited to share that soon, clinicians at connected organizations will be able to order Fulgent testing and receive results in the workflow they already use.

Learn more at the Epic Showroom now: https://showroom.epic.com/Listing?id=3661&returnTitle=6



Epic, Aura, and Epic Showroom are trademarks of Epic Systems Corporation.

Last month, our skeletal dysplasia panel grew by 188 genes, while our vascular malformation panel added 29. Our team is ...
09/02/2026

Last month, our skeletal dysplasia panel grew by 188 genes, while our vascular malformation panel added 29.

Our team is constantly working to ensure our panels are up to date, because a gene that wasn't included last month may now be the one that explains a patient's phenotype and provides the answers they seek.

As with most Fulgent tests, each panel can be tailored to a focused subset of genes to fit the clinical needs of individual patients.

Has broader panel coverage ever changed the path to a diagnosis for one of your patients? We'd like to hear how it played out.

Explore our heritable disease panel menu at https://fulgentgenetics.com/products/disease/raredisease.html

Address

4399 Santa Anita Avenue
El Monte, CA
91731

Opening Hours

Monday 7am - 6pm
Tuesday 7am - 6pm
Wednesday 7am - 6pm
Thursday 7am - 6pm
Friday 7am - 6pm

Telephone

+16263500537

Alerts

Be the first to know and let us send you an email when Fulgent Genetics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Fulgent Genetics:

Shortcuts

Share